HRGN Harvard Apparatus Regenerative Technology (HRGN) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001563665
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $717.9K priced
What the filings say about HRGN
Insiders, 180 days
+$394.5K net bought
1 buyer
Harvard Apparatus Regenerative Technology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Harvard Apparatus Regenerative Technology, Inc. insiders bought a net $394.5K of stock across 16 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Sep 11, 2026.
- -0.1% median (+2.1% mean) 90-day return after 13 previous buys.
- The trade is 0.5% of the 1,332,930 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO He Junli bought about $14.5K of HRGN on Sep 15, 2026.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Nov 25, 2025.
- -0.1% median (+2.1% mean) 90-day return after 13 previous buys.
- The trade is 27.3% of the 1,326,205 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO He Junli bought about $380.0K of HRGN on Sep 11, 2026, the largest insider purchase at the company on our record.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Sep 30, 2025.
- +1.6% median (+2.3% mean) 90-day return after 12 previous buys.
- The trade is 1.1% of the 280,575 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO He Junli bought about $5.1K of HRGN on Nov 25, 2025.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Sep 2, 2025.
- +6.1% median (+3.1% mean) 90-day return after 11 previous buys.
- The trade is 0.1% of the 277,575 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO He Junli bought about $594 of HRGN on Sep 30, 2025.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Aug 21, 2025.
- +1.6% median (+2.5% mean) 90-day return after 10 previous buys.
- The trade is 4.0% of the 277,275 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO He Junli bought about $20.8K of HRGN on Sep 2, 2025, the largest insider purchase at the company since 2023.16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$394.5K over 180 days
+$394.5K over 90 days
more than 84% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+63.7% year over year
more than 89% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HRGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+5.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HRGN: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in HRGN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HRGN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
What changed recently
Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requir
2026-09-04 · Completion moved 2026-07 → 2029-05-18
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr. Junli (Jerry) He
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$440.0K
$365.1K
$208.7K
-67%
n/a
2024
$1.3M
$894.5K
$246.3K
-46%
n/a
2023
$5.8M
$5.8M
$233.4K
-9%
n/a
2022
$37.2K
-$10
$227.5K
+174%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $394.5K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
HRGN financials
Revenue growth
+63.7%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$982.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HRGN
| FY Dec 2025 | $704.0K |
| FY Dec 2024 | $430.0K |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | $414.0K |
| Mar 2026 | $226.0K |
| Dec 2025 | $219.0K |
| Sep 2025 | $123.0K |
| Jun 2025 | $317.0K |
| Mar 2025 | $45.0K |
| Dec 2024 | $258.0K |
| Sep 2024 | $59.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM HRGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -409.4% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -575.1% |
| Mar 2025 | n/a |
| Dec 2024 | -520.9% |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$3.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HRGN
| FY Dec 2025 | -$3.8M |
| FY Dec 2024 | -$4.9M |
| FY Dec 2023 | -$7.0M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity HRGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt HRGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity HRGN
| FY Dec 2025 | -321.1% |
| FY Dec 2024 | -317.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | -636.5% |
| Dec 2025 | -321.1% |
| Sep 2025 | -242.0% |
| Jun 2025 | -2,839% |
| Mar 2025 | -662.3% |
| Dec 2024 | -317.7% |
| Sep 2024 | -252.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-349.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HRGN
| FY Dec 2025 | -193.0% |
| FY Dec 2024 | -219.2% |
| FY Dec 2023 | -359.9% |
| FY Dec 2022 | -284.7% |
| FY Dec 2021 | -404.8% |
| Jun 2026 | -349.7% |
| Mar 2026 | -261.3% |
| Dec 2025 | -193.0% |
| Sep 2025 | -166.1% |
| Jun 2025 | -203.3% |
| Mar 2025 | -187.4% |
| Dec 2024 | -219.2% |
| Sep 2024 | -182.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital HRGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed HRGN
| FY Dec 2025 | -303.0% |
| FY Dec 2024 | -305.0% |
| FY Dec 2023 | -670.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | -578.9% |
| Dec 2025 | -303.0% |
| Sep 2025 | -229.6% |
| Jun 2025 | -400.9% |
| Mar 2025 | -333.6% |
| Dec 2024 | -305.0% |
| Sep 2024 | -241.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HRGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value HRGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-10.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield HRGN
| FY Dec 2025 | -12.2% |
| FY Dec 2024 | -10.3% |
| FY Dec 2023 | -10.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -16.2% |
| Mar 2026 | -13.6% |
| Dec 2025 | -12.2% |
| Sep 2025 | -12.6% |
| Jun 2025 | -15.9% |
| Mar 2025 | -15.2% |
| Dec 2024 | -10.3% |
| Sep 2024 | -6.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HRGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $704.0K | $430.0K | $103.0K | n/a |
| Operating income | -$6.9M | -$7.7M | -$9.0M | -$6.2M |
| Net income | -$6.9M | -$7.7M | -$9.0M | -$6.1M |
| EPS (diluted) | n/a | n/a | -0.67 | -0.55 |
| Operating cash flow | -$3.8M | -$4.9M | -$6.9M | -$5.1M |
| Cash | $1.4M | $2.5M | $432.0K | $1.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
HRGN Stock Sonar score 3/7 axes
Find similar shapesCompareHRGN ranks highest on risk and compliance (96th percentile) and growth (89th), and lowest on insider conviction (68th), among Medical Devices peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HRGN filings, in plain words
Are Harvard Apparatus Regenerative Technology insiders buying or selling HRGN?
In the 180 days to 2026-10-28, Harvard Apparatus Regenerative Technology insiders were net buyers, a net $394.5K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Harvard Apparatus Regenerative Technology insiders were net buyers of HRGN, a net $394.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
